COSMIC-312, a disappointing result-is that so surprising?
作者信息
Adhoute Xavier, Bourlière Marc, Anty Rodolphe
机构信息
Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, Marseille, France.
Department of Gastroenterology and Hepatology, Hôpital Universitaire de l'Archet, Nice, France.
出版信息
Ann Transl Med. 2024 Aug 1;12(4):59. doi: 10.21037/atm-23-421. Epub 2023 Mar 2.
Abstract
摘要
相似文献
1
COSMIC-312, a disappointing result-is that so surprising?COSMIC - 312，一个令人失望的结果——这有那么令人惊讶吗？
Ann Transl Med. 2024 Aug 1;12(4):59. doi: 10.21037/atm-23-421. Epub 2023 Mar 2.
2
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.经动脉化疗栓塞联合酪氨酸激酶抑制剂加免疫检查点抑制剂与酪氨酸激酶抑制剂加免疫检查点抑制剂治疗不可切除的伴有一级或低级别门静脉癌栓的肝细胞癌。
Cardiovasc Intervent Radiol. 2024 Jun;47(6):751-761. doi: 10.1007/s00270-024-03724-x. Epub 2024 Apr 26.
3
Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.经动脉化疗栓塞在不可切除肝细胞癌的酪氨酸激酶抑制剂和免疫检查点抑制剂联合治疗时代的作用：回顾性倾向评分匹配分析。
Acad Radiol. 2024 Apr;31(4):1304-1311. doi: 10.1016/j.acra.2023.09.001. Epub 2023 Sep 27.
4
Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.经动脉化疗栓塞术的加入可改善不可切除肝细胞癌患者酪氨酸激酶和免疫检查点抑制剂治疗方案的疗效。
J Gastrointest Oncol. 2023 Aug 31;14(4):1837-1848. doi: 10.21037/jgo-23-486. Epub 2023 Aug 14.
5
Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?免疫检查点抑制剂和酪氨酸激酶抑制剂在晚期肝细胞癌患者中的应用：序贯治疗是否重要？
Asia Pac J Clin Oncol. 2023 Jun;19(3):312-319. doi: 10.1111/ajco.13837. Epub 2022 Aug 10.
6
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.放射性栓塞联合免疫检查点抑制剂治疗与放射性栓塞联合酪氨酸激酶抑制剂治疗肝细胞癌的比较。
J Vasc Interv Radiol. 2024 May;35(5):722-730.e1. doi: 10.1016/j.jvir.2024.02.004. Epub 2024 Feb 9.
7
The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.抗 PD-1/PD-L1 抗体联合 VEGF 受体酪氨酸激酶抑制剂与贝伐珠单抗治疗不可切除肝细胞癌的疗效比较。
Front Immunol. 2023 Jan 23;14:1073133. doi: 10.3389/fimmu.2023.1073133. eCollection 2023.
8
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.将免疫检查点抑制联合酪氨酸激酶抑制作为转移性肾细胞癌的一线和后续治疗。
Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18.
9
The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers.越多越好？免疫检查点抑制剂和酪氨酸激酶抑制剂联合治疗晚期实体瘤的证据和疗效。
Cancer Treat Rev. 2024 Apr;125:102718. doi: 10.1016/j.ctrv.2024.102718. Epub 2024 Mar 15.
10
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.免疫检查点抑制剂联合治疗晚期肝细胞癌的研究进展——系统综述。
Cancer Treat Rev. 2023 Jul;118:102584. doi: 10.1016/j.ctrv.2023.102584. Epub 2023 May 27.
本文引用的文献
1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.阿替利珠单抗联合贝伐单抗与乐伐替尼治疗不可切除肝细胞癌：一项全球大型真实世界研究。
Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25.
3
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.卡博替尼联合阿替利珠单抗与索拉非尼治疗晚期肝细胞癌（COSMIC-312）：一项多中心、开放标签、随机、III 期临床试验。
Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
4
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
5
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
6
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
7
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
8
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
9
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
10
Advances in molecular classification and precision oncology in hepatocellular carcinoma.肝细胞癌的分子分类和精准肿瘤学进展。
J Hepatol. 2020 Feb;72(2):215-229. doi: 10.1016/j.jhep.2019.08.017.
Zotero 插件